Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Pegcetacoplan in C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
2020-003767-25Phase 3Active
- Sponsor
- Apellis Pharmaceuticals
- Start
- Oct 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Oct 2021; status: active.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on 2020-003767-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003767-25.